Horizon Therapeutics (NASDAQ:HZNP) reported Q4 EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942 million versus the consensus estimate of $922.92 million.
Horizon Therapeutics (NASDAQ:HZNP) reported Q4 EPS of $1.21, $0.12 better than the analyst estimate of $1.09. Revenue for the quarter came in at $942 million versus the consensus estimate of $922.92 million.